Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineTrial of Deferiprone in Parkinson’s Disease

In a trial randomizing 372 participants to deferiprone or placebo, nigrostriatal iron content decreased more in the deferiprone group than in the placebo group, but that didn’t correlate to a clinical benefit. Instead, 22% of those on the chelator required initiation of dopaminergic therapy versus 2.7% of those in the placebo group.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form